Personal CFO Solutions LLC Grows Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Personal CFO Solutions LLC increased its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 248.2% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 31,483 shares of the company’s stock after purchasing an additional 22,441 shares during the quarter. Personal CFO Solutions LLC’s holdings in Teva Pharmaceutical Industries were worth $948,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of TEVA. AQR Capital Management LLC increased its position in shares of Teva Pharmaceutical Industries by 24.6% in the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after buying an additional 4,732 shares in the last quarter. Focus Partners Wealth increased its holdings in Teva Pharmaceutical Industries by 4.5% during the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after acquiring an additional 1,739 shares in the last quarter. Franklin Resources Inc. acquired a new position in Teva Pharmaceutical Industries during the second quarter worth about $255,000. Flow Traders U.S. LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at about $238,000. Finally, Cerity Partners LLC grew its position in shares of Teva Pharmaceutical Industries by 2.9% in the second quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock valued at $768,000 after purchasing an additional 1,291 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analysts Set New Price Targets

TEVA has been the subject of several research reports. Barclays lifted their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. UBS Group upped their price objective on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Piper Sandler reiterated an “overweight” rating and set a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Finally, Truist Financial raised their price target on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $41.78.

Insider Activity

In related news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the completion of the transaction, the executive vice president owned 172,184 shares of the company’s stock, valued at approximately $6,131,472.24. This represents a 47.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Amir Weiss sold 10,679 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total transaction of $384,444.00. Following the completion of the transaction, the chief accounting officer owned 20,016 shares in the company, valued at approximately $720,576. This trade represents a 34.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 465,931 shares of company stock valued at $16,332,989 in the last ninety days. 0.54% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $33.09 on Friday. The business’s 50-day moving average price is $34.19 and its 200 day moving average price is $32.68. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries Ltd. has a twelve month low of $14.99 and a twelve month high of $37.35. The company has a market capitalization of $38.04 billion, a PE ratio of 24.88, a price-to-earnings-growth ratio of 4.06 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion during the quarter. On average, research analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.97 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.